Anaesthesia for Renal Transplantation

Quick Answer

Definition: Renal transplantation is the treatment of choice for end-stage renal disease (ESRD), requiring careful anaesthetic management addressing the multi-system complications of uraemia, optimising graft perfusion, and managing immunosuppression.

Key Points for ANZCA Finals:

• ESRD Physiology: Cardiovascular disease (leading cause of death), anaemia, platelet dysfunction, hyperkalaemia, metabolic acidosis, altered drug pharmacokinetics
• Preoperative: Dialysis within 24 hours, target K+ <5.5 mmol/L, optimise volume status, cardiac assessment essential
• Drug Considerations: Avoid suxamethonium (hyperkalaemia risk), reduce doses of renally excreted drugs, protein binding changes increase free drug fraction
• Intraoperative Goals: Maintain CVP 10-15 cmH2O, MAP >70 mmHg, urine output at unclamping, avoid nephrotoxins
• Living vs Deceased Donor: Living donor has better outcomes, shorter ischaemia time; deceased donor may have longer cold ischaemia time and higher DGF risk
• Delayed Graft Function: Occurs in 20-50% of deceased donor transplants; maintain adequate perfusion and avoid nephrotoxins

---

Introduction

Renal transplantation is the gold standard treatment for end-stage renal disease (ESRD), providing superior survival and quality of life compared to dialysis. In Australia and New Zealand, approximately 900-1000 kidney transplants are performed annually, with increasing numbers of living donor transplants. [1,2]

Patients with ESRD present unique anaesthetic challenges due to multi-system dysfunction affecting cardiovascular, haematological, neurological, and metabolic systems. Understanding these pathophysiological changes is essential for safe perioperative management and optimal graft function. [3]

The anaesthetist plays a critical role in:

• Optimising the recipient's physiological state preoperatively
• Maintaining adequate graft perfusion intraoperatively
• Avoiding nephrotoxic agents and managing immunosuppression
• Preventing and treating perioperative complications

---

End-Stage Renal Disease Physiology

Cardiovascular System

Cardiovascular disease is the leading cause of death in ESRD patients, occurring at 10-20 times the rate of the general population. The cardiovascular mortality rate is approximately 9% per year in dialysis patients. [4,5]

Hypertension

Prevalence of hypertension in ESRD is 80-90%. Target blood pressure preoperatively should be <140/90 mmHg, though overly aggressive blood pressure control may compromise cerebral and coronary perfusion. [6]

Uraemic Cardiomyopathy

Uraemic cardiomyopathy is characterised by:

Echocardiography is recommended preoperatively. Left ventricular ejection fraction <40% is associated with significantly increased perioperative risk. Diastolic dysfunction makes patients sensitive to both hypovolaemia and volume overload. [7,8]

Uraemic Pericarditis

Uraemic pericarditis occurs in 2-15% of dialysis patients and is an indication for urgent dialysis before transplantation. Clinical features include:

• Chest pain (pleuritic, positional)
• Pericardial friction rub
• ECG changes (diffuse ST elevation, PR depression)
• Risk of progression to cardiac tamponade

Clinical Pearl: Uraemic pericarditis is a contraindication to elective surgery. Intensive dialysis over 1-2 weeks usually results in resolution. Pericardiocentesis or surgical drainage may be required for tamponade.

Haematological System

Anaemia of Chronic Kidney Disease

Anaemia in CKD is primarily due to reduced erythropoietin production. Erythropoiesis-stimulating agents (ESAs) are used to maintain haemoglobin 100-115 g/L. Higher targets (>130 g/L) are associated with increased cardiovascular events and mortality. [9,10]

Uraemic Coagulopathy

Uraemic bleeding diathesis results from platelet dysfunction:

Management options include:

• Desmopressin (DDAVP): 0.3 mcg/kg IV over 30 minutes, onset 30-60 minutes, duration 6-8 hours
• Cryoprecipitate: Contains vWF and fibrinogen
• Conjugated oestrogens: 0.6 mg/kg/day for 5 days, prolonged effect
• Correction of anaemia: Haematocrit >30% improves platelet function
• Dialysis: Removes uraemic toxins affecting platelet function [11,12]

Metabolic Derangements

Hyperkalaemia

Hyperkalaemia is the most life-threatening electrolyte disturbance in ESRD:

Management of Hyperkalaemia:

Target serum potassium <5.5 mmol/L before surgery. [13,14]

Metabolic Acidosis

Chronic metabolic acidosis (pH 7.30-7.35, bicarbonate 18-22 mmol/L) is common in ESRD due to:

• Reduced acid excretion
• Loss of bicarbonate regeneration capacity
• Accumulation of organic acids

Implications for anaesthesia:

• Compensatory hyperventilation may mask respiratory depression
• Acidosis shifts oxygen-haemoglobin dissociation curve rightward
• Acidosis potentiates hyperkalaemia effects on cardiac conduction
• Severe acidosis (pH <7.20) reduces myocardial contractility and vasopressor response

Uraemia

Elevated blood urea nitrogen (BUN) >30 mmol/L causes:

• Uraemic encephalopathy (confusion, seizures)
• Uraemic gastropathy (nausea, vomiting, GI bleeding)
• Impaired immune function
• Autonomic neuropathy
• Peripheral neuropathy

Pharmacological Implications

Drug handling is significantly altered in ESRD:

Key Pharmacological Principles:

• Reduce doses of renally excreted drugs
• Expect prolonged duration of action
• Increased free fraction increases both efficacy and toxicity
• Active metabolites may accumulate (e.g., morphine-6-glucuronide)

---

Preoperative Assessment

Dialysis Status and Timing

Optimal Dialysis Timing:

Dialysis on the day of surgery allows optimisation of electrolytes and fluid status. However, patients may be hypovolaemic post-dialysis, which can compromise graft perfusion. A balance must be achieved. [15,16]

Haemodialysis vs Peritoneal Dialysis:

Volume Status Assessment

Accurate volume assessment is challenging in ESRD patients:

Volume Status Goals:

• Avoid hypovolaemia: Compromises graft perfusion
• Avoid hypervolaemia: Risk of pulmonary oedema, cardiac decompensation
• Target: Slight positive fluid balance at time of graft reperfusion

Cardiac Assessment

Given the high prevalence of cardiovascular disease, cardiac assessment is essential:

Minimum Evaluation:

• 12-lead ECG: LVH, ischaemia, conduction abnormalities
• Echocardiography: LV function, diastolic function, valvular disease
• Functional capacity assessment: NYHA class, exercise tolerance

Further Evaluation (If Indicated):

• Stress testing: Dobutamine stress echo or pharmacological nuclear imaging
• Coronary angiography: If stress test positive or high clinical suspicion
• Cardiology consultation: For significant abnormalities

The Australian and New Zealand Transplant Society (ANZOTS) guidelines recommend cardiac evaluation in all transplant candidates, with functional testing in those with diabetes, prior cardiovascular disease, or multiple risk factors. [17,18]

Airway and Other Considerations

---

Drug Considerations in ESRD

Neuromuscular Blocking Agents

Suxamethonium

Critical Warning: Suxamethonium causes a transient rise in serum potassium of 0.5-1.0 mmol/L. In patients with pre-existing hyperkalaemia, this may precipitate life-threatening arrhythmias and cardiac arrest.

Non-Depolarising Agents

Cisatracurium is the preferred agent due to organ-independent Hofmann degradation. Quantitative neuromuscular monitoring (TOF ratio) is mandatory. [19,20]

Opioids

Clinical Pearl: Fentanyl and remifentanil are the preferred opioids in ESRD due to inactive metabolites and minimal renal excretion. Avoid morphine due to accumulation of the active metabolite morphine-6-glucuronide. [21,22]

Induction Agents

Propofol remains the induction agent of choice but requires dose reduction due to increased free fraction from hypoalbuminaemia and displacement by uraemic toxins. [23]

Volatile Agents

Sevoflurane produces Compound A (fluoromethyl-2,2-difluoro-1-[trifluoromethyl]vinyl ether) when exposed to CO2 absorbents. Although nephrotoxic in rats, no clinical evidence of nephrotoxicity exists in humans, including renal transplant patients. Fresh gas flows >2 L/min minimise Compound A production. [24]

Other Agents

---

Intraoperative Management

Monitoring

Standard Monitoring:

• ECG with ST-segment analysis
• Pulse oximetry
• Capnography
• Temperature (oesophageal or nasopharyngeal)
• Neuromuscular monitoring (quantitative TOF)

Invasive Monitoring:

Important: Avoid arteriovenous fistula arm for blood pressure monitoring, venous access, and arterial line placement. Protect the fistula throughout surgery.

Fluid Management

Adequate hydration is critical for graft function. Hypovolaemia at reperfusion is associated with delayed graft function.

Fluid Strategy:

Fluid Considerations:

• 0.9% Saline: Contains 154 mmol/L chloride; large volumes cause hyperchloraemic acidosis and may impair renal function
• Balanced crystalloids (Plasmalyte, Hartmann's): Physiological chloride content; preferred for large-volume resuscitation
• Colloids: Albumin 4% safe; avoid hydroxyethyl starch (HES) - associated with AKI in critically ill patients

Target CVP 10-15 cmH2O at the time of graft reperfusion to ensure adequate graft perfusion pressure. Some centres use goal-directed fluid therapy with stroke volume variation or oesophageal Doppler. [25,26]

Maintaining Graft Perfusion

Haemodynamic Targets:

Vasopressors:

• Avoid vasoconstrictors if possible (may reduce graft blood flow)
• If vasopressor required: low-dose noradrenaline preferred
• Dopamine: No evidence of "renal dose" benefit; may cause tachycardia

At Unclamping:

• Expect hypotension due to ischaemia-reperfusion and release of vasodilatory metabolites from the graft
• Pre-treat with fluid loading to CVP 10-15 cmH2O
• Have vasopressor ready if needed
• Surgeon may request furosemide (40-80 mg) or mannitol (0.5-1 g/kg) at unclamping

Immunosuppression

Immunosuppressive agents are administered perioperatively:

Anaesthetic Technique

General Anaesthesia:

Regional Anaesthesia:

• Epidural anaesthesia: Limited use due to uraemic coagulopathy risk
• Transversus abdominis plane (TAP) block: Useful adjunct for postoperative analgesia
• Wound infiltration: Local anaesthetic infiltration by surgeon

---

Living vs Deceased Donor Considerations

Living Donor Transplantation

Advantages:

• Shorter cold ischaemia time (<2 hours typically)
• Better graft function and survival
• Lower delayed graft function rates (5-10% vs 20-50%)
• Planned, elective procedure with optimised recipient
• Better HLA matching possible

Anaesthetic Considerations:

• Coordinated surgery with donor nephrectomy (often laparoscopic)
• Timing is critical: Minimise warm ischaemia time
• Communication between operating teams essential

Deceased Donor Transplantation

Donor Types:

Cold Ischaemia Time:

• Definition: Time from cold perfusion of donor kidney to reperfusion in recipient
• Target: <12 hours (optimal); acceptable up to 24 hours
• Every hour of cold ischaemia increases DGF risk by 4-5%

Emergency Nature:

• Deceased donor transplants are often performed at night or on weekends
• Recipient may not be recently dialysed
• More thorough preoperative assessment and optimisation may be needed [27,28]

---

Postoperative Care

Immediate Postoperative Management

Monitoring:

• High-dependency or intensive care unit for 12-24 hours
• Continuous ECG, pulse oximetry, blood pressure monitoring
• Hourly urine output measurement
• Strict fluid balance charting

Urine Output:

• Living donor: Typically immediate diuresis
• Deceased donor: May have delayed graft function (oliguria <400 mL/day)
• Replace urine output mL for mL with crystalloid initially
• Avoid hypovolaemia which may compromise graft perfusion

Delayed Graft Function (DGF)

Definition: Need for dialysis within the first week post-transplant

Incidence:

• Living donor: 5-10%
• Deceased donor (DBD): 20-30%
• Deceased donor (DCD): 30-50%

Risk Factors:

Management:

• Continue dialysis as needed
• Maintain adequate graft perfusion (avoid hypotension, hypovolaemia)
• Avoid nephrotoxic agents
• Immunosuppression continues despite DGF
• Most recover function within 2-4 weeks [29,30]

Immunosuppression Management

Standard Immunosuppression Protocol:

Anaesthetic Implications:

• Immunosuppressed patients at risk of opportunistic infections
• Strict aseptic technique essential
• Avoid live vaccines perioperatively
• Drug interactions with immunosuppressants (e.g., calcium channel blockers affect tacrolimus levels)

Complications

Early Complications:

---

ANZCA Examination Focus

Commonly Examined Topics

Key Learning Points for ANZCA Candidates

1. Cardiovascular assessment is essential: 50% of ESRD patients have significant cardiac disease; echo and functional assessment required
2. Dialysis within 24 hours of surgery with K+ <5.5 mmol/L
3. AVOID suxamethonium in hyperkalaemia; cisatracurium is the preferred NMBA
4. Fentanyl and remifentanil are the preferred opioids; avoid morphine (M6G accumulation)
5. CVP 10-15 cmH2O at reperfusion to ensure graft perfusion
6. Living donor transplants have better outcomes and lower DGF rates
7. Protect the AV fistula throughout the perioperative period

Viva Preparation Tips

• Practice describing ESRD pathophysiology systematically by organ system
• Know the drug dosing adjustments for renally excreted agents
• Be prepared to manage intraoperative hyperkalaemia
• Understand the differences between living and deceased donor transplantation
• Know the management of delayed graft function

---

Assessment Content

SAQ Practice Question

Question: A 58-year-old man with end-stage renal disease secondary to diabetic nephropathy presents for deceased donor renal transplantation. He has been on haemodialysis for 4 years. His last dialysis was 36 hours ago due to the urgent nature of the transplant. His blood pressure is 160/95 mmHg, heart rate 88 bpm. Pre-operative investigations show: K+ 5.8 mmol/L, Hb 95 g/L, Cr 850 μmol/L, pH 7.30, HCO3- 18 mmol/L.

(a) Outline the cardiovascular manifestations of end-stage renal disease and their implications for anaesthesia. (6 marks)

(b) Describe your approach to managing this patient's hyperkalaemia before and during anaesthesia. (6 marks)

(c) Outline your intraoperative management strategy to optimise graft function at the time of reperfusion. (8 marks)

---

Model Answer

(a) Cardiovascular Manifestations of ESRD (6 marks)

Hypertension (1.5 marks)

• Prevalence 80-90% in ESRD
• Mechanisms: volume overload, RAAS activation, sympathetic overactivity, endothelial dysfunction
• Anaesthetic implications: preload dependence, sensitive to vasodilators, increased afterload, accelerated atherosclerosis
• This patient has BP 160/95, indicating suboptimal control

Uraemic Cardiomyopathy (2 marks)

• Left ventricular hypertrophy (70-80%): pressure and volume overload
• Diastolic dysfunction (50-70%): myocardial fibrosis, sensitive to preload changes
• Systolic dysfunction (15-30%): reduced contractile reserve
• Anaesthetic implications: sensitive to both hypovolaemia and fluid overload, reduced cardiac reserve, diastolic dysfunction limits fluid tolerance

Coronary Artery Disease (1.5 marks)

• Prevalence 40-50%, often asymptomatic
• Accelerated atherosclerosis due to traditional and uraemic risk factors
• This patient has diabetes, adding to cardiovascular risk
• Anaesthetic implications: maintain myocardial oxygen supply-demand balance, avoid tachycardia and hypotension

Other Cardiovascular Manifestations (1 mark)

• Uraemic pericarditis (2-15%): chest pain, tamponade risk
• Arrhythmias: electrolyte disturbances, autonomic dysfunction
• Autonomic neuropathy: impaired heart rate variability, orthostatic hypotension, reduced response to vasoactive drugs

(b) Management of Hyperkalaemia (6 marks)

Immediate Assessment (1 mark)

• K+ 5.8 mmol/L is moderately elevated
• Obtain 12-lead ECG: assess for peaked T waves, prolonged PR, widened QRS
• Review timing of last dialysis (36 hours) and reason for delay
• Avoid suxamethonium (K+ rise of 0.5-1.0 mmol/L could cause arrhythmias)

Pre-operative Treatment Options (3 marks)

Recommended Approach:

• Give calcium gluconate immediately for cardiac membrane stabilisation
• Administer insulin/glucose for sustained K+ lowering
• Consider urgent dialysis if time permits and K+ remains >6.0 mmol/L

Intraoperative Management (2 marks)

• Continuous ECG monitoring with ST-segment analysis
• Avoid suxamethonium: use rocuronium 1.0-1.2 mg/kg for rapid sequence if required
• Avoid blood products that may worsen hyperkalaemia (irradiated blood has higher K+)
• Repeat K+ measurement intraoperatively
• Have calcium gluconate and insulin/dextrose immediately available
• Consider intraoperative dialysis catheter if severe refractory hyperkalaemia

(c) Intraoperative Management to Optimise Graft Function (8 marks)

Monitoring (1.5 marks)

• Arterial line: continuous BP monitoring, frequent ABG sampling
• Central venous catheter: CVP monitoring, vasopressor/fluid access
• Urine catheter: hourly output measurement
• Temperature monitoring: prevent hypothermia (reduces graft perfusion)
• Avoid AV fistula arm for monitoring and access

Fluid Management (2 marks)

• Target CVP 10-15 cmH2O at time of graft reperfusion
• Use balanced crystalloid (Plasmalyte preferred over 0.9% saline)
• Avoid large volumes of 0.9% saline (hyperchloraemic acidosis impairs renal function)
• Goal-directed fluid therapy if available (stroke volume optimisation)
• Avoid hypovolaemia: associated with delayed graft function

Haemodynamic Goals (2 marks)

• Mean arterial pressure >70 mmHg throughout
• Optimise cardiac output: adequate preload, appropriate vasopressor if needed
• Avoid excessive vasopressor use (may reduce graft blood flow)
• If vasopressor required: low-dose noradrenaline preferred
• Maintain heart rate 60-80 bpm (optimise cardiac output, coronary perfusion)

At Time of Unclamping (1.5 marks)

• Ensure CVP 10-15 cmH2O before unclamping
• Expect transient hypotension (release of ischaemic metabolites)
• Have vasopressor ready but avoid if possible
• Surgeon may request:
  • Furosemide 40-80 mg IV to promote diuresis
  • Mannitol 0.5-1 g/kg for osmotic diuresis and free radical scavenging

Avoidance of Nephrotoxins (1 mark)

• Avoid NSAIDs
• Avoid aminoglycosides if possible
• Use balanced crystalloids (avoid excessive 0.9% saline)
• Avoid contrast agents
• Maintain adequate perfusion pressure to prevent ischaemic injury

---

Viva Scenario

Scenario: You are the anaesthetist for a 45-year-old woman receiving a living donor renal transplant from her brother. She has been on peritoneal dialysis for 2 years for ESRD secondary to IgA nephropathy. Her last peritoneal dialysis exchange was this morning. Blood pressure is 140/85 mmHg, heart rate 70 bpm. K+ is 5.2 mmol/L, Hb 105 g/L.

---

Examiner: What are your key concerns for this patient?

Candidate: This patient presents several anaesthetic considerations related to her ESRD:

Cardiovascular: With 2 years of dialysis, she is at risk of hypertension, left ventricular hypertrophy, and diastolic dysfunction. Her BP of 140/85 suggests reasonable control. I would want to review her echocardiogram for LV function and any valvular abnormalities.

Electrolyte status: Her K+ of 5.2 mmol/L is acceptable (<5.5 mmol/L), allowing me to proceed safely. However, I would still avoid suxamethonium and use cisatracurium or rocuronium for neuromuscular blockade.

Haematological: Hb of 105 g/L is within the target range for ESRD (100-115 g/L). Uraemic platelet dysfunction may be present, increasing bleeding risk.

Fluid status: Peritoneal dialysis this morning suggests her fluid and electrolyte status should be relatively optimised. However, she may still have some degree of fluid overload or depletion depending on exchange volumes.

Living donor advantage: This is a planned procedure with a living donor, so cold ischaemia time will be minimal (<2 hours), which is associated with better graft function and lower delayed graft function rates.

---

Examiner: How would you assess her cardiovascular status preoperatively?

Candidate: I would perform a comprehensive cardiovascular assessment:

History:

• Exercise tolerance and functional capacity (NYHA class)
• Symptoms of cardiac disease: chest pain, dyspnoea, orthopnoea, PND, palpitations
• Previous cardiac events or interventions
• Duration of dialysis (longer duration = higher cardiac risk)

Physical examination:

• Blood pressure (both arms)
• Heart sounds (S3, S4, murmurs)
• JVP assessment
• Peripheral oedema
• Lung auscultation for pulmonary oedema

Investigations:

• 12-lead ECG: LVH, ischaemia, conduction abnormalities, arrhythmias
• Echocardiography: LV function (LVEF), diastolic function (E/e' ratio), LV mass, valvular disease
• Consider stress testing if: poor or unknown functional capacity, multiple cardiac risk factors, or concerning symptoms

For this 45-year-old woman with relatively short dialysis vintage (2 years) and IgA nephropathy (not diabetic), her cardiovascular risk is likely moderate. An echocardiogram within the past 12 months showing preserved LV function would be reassuring.

---

Examiner: You proceed with the case. At the time of vascular unclamping, the blood pressure drops from 110/70 to 75/45 mmHg. What is your approach?

Candidate: This hypotension at unclamping is expected but requires prompt management:

Immediate Assessment:

• Confirm the reading (arterial line waveform quality)
• Assess heart rate: Is there bradycardia or tachycardia?
• Check CVP: Was the target of 10-15 cmH2O achieved?
• Check for surgical bleeding

Mechanism:

• Release of vasodilatory metabolites (adenosine, potassium, lactate) from the ischaemic graft
• Reperfusion of the graft vasculature creating a "third space" effect
• This is usually transient (5-10 minutes)

Immediate Treatment:

1. Fluid bolus: 250-500 mL crystalloid if CVP <10 cmH2O
2. Vasopressor: If hypotension persists despite adequate filling:
   • Phenylephrine 50-100 mcg bolus (pure vasoconstrictor)
   • Or metaraminol 0.5-1 mg bolus
   • If sustained: low-dose noradrenaline infusion (0.05-0.1 mcg/kg/min)
3. Communicate with surgeon: Inform them of haemodynamic instability
4. Check for surgical cause: Bleeding, vascular problem

Considerations:

• Avoid excessive vasopressor use if possible, as vasoconstriction may reduce graft blood flow
• However, adequate MAP (>70 mmHg) is essential for graft perfusion
• Balance between systemic perfusion pressure and local vasoconstriction

---

Examiner: The surgeon asks you about using dopamine to improve graft perfusion. What is your response?

Candidate: This is an area where evidence has evolved over time.

Historical "Renal-Dose" Dopamine:

• Dopamine at 1-3 mcg/kg/min was traditionally thought to selectively dilate renal vasculature and improve renal blood flow
• The concept was that low-dose dopamine would stimulate dopaminergic (DA1) receptors in renal vasculature, causing vasodilation

Current Evidence:

• Multiple systematic reviews and meta-analyses have shown NO benefit of "renal-dose" dopamine for preventing or treating acute kidney injury
• The ANZICS CTG study (Bellomo 2000) found no benefit in critically ill patients with early renal dysfunction
• A Cochrane review (2005) concluded that dopamine does not prevent mortality, onset of acute renal failure, or need for dialysis

My Response to the Surgeon: "I understand the historical rationale, but current evidence does not support the use of low-dose dopamine for renal protection. Meta-analyses have shown no benefit in preventing acute kidney injury or improving outcomes.

For maintaining graft perfusion, I would focus on:

1. Ensuring adequate intravascular volume (CVP 10-15 cmH2O)
2. Maintaining mean arterial pressure >70 mmHg
3. Avoiding nephrotoxic agents
4. If a vasopressor is needed, I would use low-dose noradrenaline rather than dopamine, as it provides more predictable haemodynamic effects without the risk of dopamine-induced tachycardia."

---

Examiner: The graft produces 500 mL of urine in the first hour. How do you manage this?

Candidate: This is excellent news—immediate graft function with good urine output is a positive prognostic sign.

Fluid Replacement:

• Initially, replace urine output mL for mL with crystalloid (Plasmalyte or Hartmann's)
• This prevents hypovolaemia and maintains graft perfusion
• As diuresis continues, can reduce replacement to 50-75% of urine output to avoid fluid overload

Electrolyte Management:

• High urine output can lead to electrolyte losses
• Monitor serum potassium: diuresis may cause hypokalaemia
• Monitor serum sodium, magnesium, phosphate
• Adjust replacement fluids based on laboratory results

Ongoing Monitoring:

• Continue hourly urine output measurement
• Regular ABG and electrolytes (every 2-4 hours initially)
• Maintain CVP 8-12 cmH2O (slightly lower now that graft is functioning)
• Maintain MAP >70 mmHg

Communication:

• Document urine output for surgical team
• Handover to recovery/HDU staff with clear fluid replacement protocol
• Ensure overnight team aware of target urine output and replacement strategy

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples

Aboriginal and Torres Strait Islander Australians experience disproportionately high rates of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The incidence of treated ESRD is 6-8 times higher in Indigenous Australians compared to non-Indigenous Australians, with even greater disparities in remote communities where rates may be 20-30 times higher. [31,32]

Key Considerations for Anaesthetists:

Access to Transplantation

• Indigenous Australians have significantly lower rates of kidney transplantation despite higher rates of ESRD
• Barriers include: geographic isolation, comorbidities affecting eligibility, cultural factors, limited donor availability
• Many Indigenous patients must relocate to urban centres for dialysis and transplant assessment, away from family and Country

Comorbidities

• Higher prevalence of diabetes mellitus (major cause of ESRD in Indigenous populations)
• Higher rates of cardiovascular disease at younger ages
• Rheumatic heart disease remains prevalent in some communities
• These comorbidities increase anaesthetic risk and require thorough preoperative assessment

Cultural Safety

• Involve Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs) in perioperative care
• Family and community involvement in decision-making is essential; allow time for this process
• Ensure interpreters are available for patients whose first language is not English
• Recognise that consent processes may need adaptation for oral traditions
• Be aware of cultural beliefs about organ donation and transplantation

Perioperative Communication

• Use plain language, avoid medical jargon
• Check understanding using teach-back methods
• Allow time for questions and family consultation
• Respect the role of Elders in decision-making

Postoperative Considerations

• Long-term follow-up may be challenging for patients from remote communities
• Coordinate with local health services for ongoing care
• Telemedicine can support follow-up in remote areas
• Consider cultural and family support needs during hospitalisation away from home

Māori Health (New Zealand)

Māori have approximately twice the rate of ESRD compared to non-Māori New Zealanders. Similar disparities exist in access to transplantation.

Key Considerations:

• Involve whānau (extended family) in perioperative discussions
• Engage Māori Health Workers for cultural support
• Respect tikanga (cultural protocols) and manaakitanga (hospitality/care)
• Be aware of cultural perspectives on body integrity and organ transplantation
• Recognise that Māori patients may face geographic and socioeconomic barriers to specialist care [33]

---

Key Evidence Summary

---

References

1. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). 44th Annual Report. Adelaide: ANZDATA; 2024. Available from: www.anzdata.org.au

2. Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1 Suppl 1):S11-S103. PMID: 32301874

3. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med. 1994;331(6):365-376. PMID: 7832839

4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112-S119. PMID: 9820470

5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils. Circulation. 2003;108(17):2154-2169. PMID: 14581387

6. Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29(3):672-681. PMID: 24398888

7. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186-192. PMID: 7731145

8. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47(3):884-890. PMID: 7752588

9. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098. PMID: 17108343

10. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084. PMID: 17108342

11. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3(3):138-153. PMID: 17322926

12. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983;308(1):8-12. PMID: 6401193

13. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156-1162. PMID: 19546417

14. Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesth Analg. 2000;91(1):237-241. PMID: 10866919

15. Eschbach JW. Erythropoietin 1991—an overview. Am J Kidney Dis. 1991;18(4 Suppl 1):3-9. PMID: 1928074

16. Basile C, Lomonte C, Vernaglione L, et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant. 2008;23(1):282-287. PMID: 17942475

17. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001;1 Suppl 2:3-95. PMID: 12108435

18. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association. Circulation. 2012;126(5):617-663. PMID: 22753303

19. De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth. 1996;76(5):624-628. PMID: 8688259

20. Eastwood JB, Parker B. Cisatracurium and end-stage renal failure. Br J Anaesth. 1996;77(3):425-426. PMID: 8949824

21. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504. PMID: 15504625

22. Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 1993;54(2):158-167. PMID: 8354025

23. Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. Br J Anaesth. 1998;81(6):854-860. PMID: 10211008

24. Conzen PF, Nuscheler M, Melotte A, et al. Renal function and serum fluoride concentrations in patients with stable renal insufficiency after anesthesia with sevoflurane or enflurane. Anesth Analg. 1995;81(3):569-575. PMID: 7653824

25. Othman MM, Ismael AZ, Hammouda GE. The impact of timing of maximal crystalloid hydration on early graft function during kidney transplantation. Anesth Analg. 2010;110(5):1440-1446. PMID: 20237045

26. Friedrich JO, Adhikari N, Herridge MS, Bhylin HD. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142(7):510-524. PMID: 15809463

27. Snoeijs MG, Winkens B, Heemskerk MB, et al. Kidney transplantation from donors after cardiac death: a 25-year experience. Transplantation. 2010;90(10):1106-1112. PMID: 20861800

28. Summers DM, Watson CJ, Pettigrew GJ, et al. Kidney donation after circulatory death (DCD): state of the art. Kidney Int. 2015;88(2):241-249. PMID: 25786101

29. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24(3):1039-1047. PMID: 19103734

30. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004;364(9447):1814-1827. PMID: 15541456

31. Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. End-stage renal disease in indigenous Australians: a disease of disadvantage. Ethn Dis. 2002;12(3):373-378. PMID: 12148708

32. McDonald SP, Russ GR. Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. Kidney Int Suppl. 2003;(83):S123-S127. PMID: 12864889

33. Metcalfe S, Beyene K, Laking G. Māori health outcomes: life expectancy. N Z Med J. 2017;130(1459):46-48. PMID: 28772545